Full Press Release Details
Immutep to Participate in The JMP Securities Hematology and Oncology Summit.
IMMP
Immutep to Participate in The JMP Securities Hematology and Oncology Summit
Key Takeaway: Immutep to Participate in The JMP Securities Hematology and Oncology Summit
Price reaction · baseline $2.4 (2022-11-30 close) · hit after-hours · 1 other IMMP headline(s) in the window, move may be shared
day 0 close · peak
+5.4%
day 1
+2.9%
day 3
-5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)